Asher Bio
YC S19San Francisco, US · 3 employees · 3 known investors
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity. The company is advancing etakafusp alfa, a cis-targeting IL-2 candidate, for solid tumor treatment and applying its platform to oncology and infectious disease indications.
Founders & leadership· Y Combinator alumni (S19)
Investors · 3
In the news
- Asher Bio Closes $55M Series C Financingfinsmes.com · 2024
- Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials - Asher Bioasherbio.com · 2024
- The Power of Immunotherapy Brings Hope to Patients | Inside Precision Medicineinsideprecisionmedicine.com · 2023
- Lonza Will Manufacture Asher Bio's Cis-targeted IL-2 Fusion Proteingenengnews.com · 2022
- Asher Bio snags $108M series B for immunotherapy programs, push into the clinic | FierceBiotechfiercebiotech.com · 2021
- Asher Bio Raises $108M in Series B Funding - FinSMEsfinsmes.com · 2021
- Asher raises $55M; Roche's Huntington's trial; EpimAb bags $120Mdelveinsight.com · 2021
- Asher Bio adds $55M and takes a page from nature for cancer immunotherapy - MedCity Newsmedcitynews.com · 2021